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dren receiving chronic PD. The presence of a gastrostomy doesFungal peritonitis in children receiving peritoneal dialysis: A
not appear to predispose patients to the development of thisreport of the NAPRTCS.
infection, and successful therapy most often consists of a combi-Background. The rarity of fungal peritonitis (FP) in children
nation of antifungal medication and dialysis catheter removal.receiving chronic peritoneal dialysis (PD) has limited the
The outcome of FP in children appears to be more favorableamount of information available regarding the risk factors and
than in the adult dialysis population.management associated with this infection.
Methods. We reviewed all cases of FP occurring in patients
entered into the dialysis registry of the NAPRTCS between
January 1992 and May 1996 in an attempt to identify risk
Fungal peritonitis (FP) is an infrequent but potentiallyfactors for infection, treatment strategies, and patient outcome
serious complication of chronic peritoneal dialysis (PD).data. A total of 1592 patients who were less than 21 years of
age were enrolled in the dialysis registry and received mainte- In pediatrics, this infection represents less than 2% of
nance PD during the period of observation. all peritonitis episodes [1, 2]. The few reports of FP in
Results. Of the total 1729 episodes of peritonitis in these children all reflect the frequent need to convert patientspatients occurring over 1732 patient-years of follow-up, FP
to hemodialysis (HD) following treatment of the fungalaccounted for 51 (2.9%) of the episodes. The patients on PD
infection [3–7]. In addition, one report has suggested thatwho developed FP were similar to those who did not develop
FP with regard to race, gender, dialysis modality, and dialysis the presence of a gastrostomy may predispose patients to
access characteristics. The overall peritonitis rate in patients the development of FP [5]. While this potential associa-
who developed FP was 2.2 episodes per patient-year compared tion has likely hindered the more widespread applicationwith 0.96 episodes per patient-year in the patients who did not
of gastrostomy feedings in the PD population, this issuedevelop this infection (P , 0.0001). In 25 (49%) cases, the FP
and others related to FP have not been confirmed orwas the patient’s initial episode of peritonitis. Whereas recent
antibiotic usage was present in 23 (56%) of 41 patients with studied in a large pediatric population to date.
FP, there was no statistically significant relationship (P 5 0.26) Accordingly, the objective of this study was to describe,
noted between the presence of a gastrostomy and the develop- to our knowledge for the first time, a multicenter pediatricment of FP. Candida species caused 33 of 42 (78.6%) FP epi-
experience with FP in pediatric patients receiving chronicsodes. Therapy consisted of PD catheter removal and Ampho-
PD, with particular attention to potential predisposingtericin B in the majority of patients. Six months after diagnosis,
27 patients remained on PD, twelve patients were receiving factors, treatment, and patient outcome data.
hemodialysis, and only three patients had died, in each case
for reasons unrelated to their FP episode.
Conclusion. FP is an infrequent cause of peritonitis in chil- METHODS
The information that comprises the dialysis portion of
the NAPRTCS database is derived from the voluntary1 The North American Pediatric Renal Transplant Cooperative Study
(NAPRTCS) is a voluntary collaborative effort comprised of over 130 submission of data from centers in the United States,
pediatric renal disease treatment centers in the United States, Canada, Canada, Mexico, and Costa Rica, where chronic pediat-
Mexico, and Costa Rica. It is supported by major, unrestricted educa-
ric dialysis is performed. For dialysis patients (HD andtional grants from Novartis, AMGEN, and Genentech. Participating
NAPRTCS centers are listed in the most recent NAPRTCS Annual PD), an initial registration form is followed by status
Report (Feld et al, Pediatr Transplant 1:146–162, 1997). forms submitted to the data coordinating center 30 days
after enrollment, six months after enrollment, and everyKey words: chronic peritoneal dialysis, infection, gastrostomy, end-
stage renal disease, Tenckhoff curled catheter. six months thereafter. For the purposes of this study,
the dialysis registry of the database was reviewed for allReceived for publication July 30, 1999
cases of FP (N 5 51) occurring in patients entering theand in revised form January 12, 2000
Accepted for publication February 2, 2000 registry between January 1992 and May 1996. Data de-
rived directly from the database included the following:Ó 2000 by the International Society of Nephrology
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Table 1. Patient profile(1) patient age, gender, and race; (2) primary renal diag-
nosis; and (3) PD catheter characteristics (catheter type, FP patients CPD patients
Demographics (N 5 51) (N 5 1541)tunnel configuration, and number of catheter cuffs). Ad-
Genderditional information was collected from case report
Male 32 (63%) 843 (55%)forms that were distributed to the NAPRTCS principal
Female 19 (37%) 685 (44%)
investigator for each episode of FP. Forty-two (82%) of Race
White 29 (57%) 873 (57%)the forms were returned with some or all of the requested
Black 8 (16%) 313 (20%)information provided, resulting in a variable number of
Hispanic 10 (20%) 270 (18%)
responses to issues detailed in the Results section. Infor- Other 4 (8%) 85 (6%)
Agemation requested on the case report form included the
0–1 year 13 (25%) 228 (15%)following: (1) specific type of fungus causing peritonitis;
2–5 years 8 (16%) 188 (12%)
(2) whether antibiotic usage preceded (within ,30 days) 6–12 years 13 (25%) 494 (32%)
13–17 years 14 (27%) 522 (34%)the fungal infection; (3) other potential predisposing
.17 years 3 (6%) 109 (7%)factors; (4) treatment of FP; and (5) patient outcome.
Primary diagnosis
An additional questionnaire was distributed to select Structural 26 (51%) 649 (42%)
GN 4 (8%) 233 (15%)NAPRTCS centers to compare how frequently a gastros-
FSGS 4 (8%) 219 (14%)tomy tube/button was present in the 51 patients with and
Other 17 (33%) 440 (29%)
203 patients without a history of FP. The questionnaire
Abbreviations are: FP, fungal peritonitis; CPD, continuous peritoneal dialysis;completion rates for FP patients and age-matched con- Structural, obstructive uropathy or hypoplastic/dysplastic kidneys; GN, glomeru-
lonephritis; FSGS, focal segmental glomerulosclerosis.trols were 88% (45 patients) and 92% (186 patients),
respectively.
Statistics
of peritonitis (bacterial, fungal, and culture negative) inDemographics and baseline characteristics were com-
patients who developed FP was 2.21 episodes per patient-pared between patients with and without a history of
year versus 0.96 episodes per patient-year for patientsFP using chi-square tests or, when appropriate, Fisher’s
without a history of FP (P , 0.0001).exact tests. A comparison of FP rates by age and total
Demographic data were evaluated for all patients inperitonitis rates between patients with and without a
the dialysis database to allow for a comparison of fea-history of FP was performed using the likelihood ratio
tures for patients with and without a history of FP. Theretest (LRT) and Poisson regression. The presence of gas-
was no significant difference in the two groups of patientstrostomy was compared between the two patient groups
for race and gender (Table 1). The greatest percentageusing chi-square tests. For patients with FP, conversion
of patients from both groups developed end-stage renalto HD was compared with the type of FP (Candida
disease (ESRD) secondary to either obstructive uropa-albicans vs. other), combination drug therapy (two or
thy or hypoplastic/dysplastic kidneys. Two thirds of eachmore antifungals used), and the time of catheter removal
group received automated PD (APD) as their dialysisfollowing peritonitis diagnosis using chi-square tests, or
modality. Greater than 50% of patients with and withoutwhen appropriate, Fisher’s exact tests. Totals in some
a history of FP used a Tenckhoff curled catheter. Intables may not equal the overall sample size because of
addition, nearly two thirds of each patient group hadmissing data. An alpha of 0.05 was used to determine
catheters with a single cuff. The distribution of exit-sitestatistical significance.
orientation for the two groups was also nearly identical,
with slightly fewer than 50% of each group using a cathe-
RESULTS ter with a laterally oriented exit site.
Only 12 (23.5%) of the 51 FP episodes were immedi-A total of 1592 patients who were less than 21 years
ately (,2 months) preceded by bacterial peritonitis. Inof age were enrolled in the dialysis registry and received
25 (49%) patients, the fungal infection was the patient’smaintenance PD during the period of observation. Of
initial episode of peritonitis. Four (7.8%) of the FP epi-the total 1729 episodes of peritonitis in these patients
sodes were preceded by a catheter exit-site/tunnel infec-occurring over 1732 years of PD follow-up, there were 51
tion, and in 23 (56%) of 41 FP episodes, the patients hadepisodes of FP in 51 patients, accounting for 2.9% of all
received antibiotics within one month of the peritonealperitonitis episodes. Approximately 25% of the patients
infection. In 10 (50%) of 20 patients who had receivedwith FP fell in the 0- to 1-year, 6- to 12-year, and 13- to
prior antibiotics, some form of antifungal prophylaxis17-year age groups, respectively (Table 1). The FP rates
was used.by age are presented in Table 2. The rate of FP in children
Of 45 patients who developed FP and who completedless than six years of age was significantly greater than
the FP rate in older children (P 5 0.029). Overall, the rate the gastrostomy questionnaire, 11 (24%) had a gastros-
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Table 2. Fungal peritonitis rates by age
Number of Years of Annualized Expected time between
Age years episodes follow-up rate episodes months
0–1 13 246 0.05 226.6
2–5 8 206 0.04 309.1
6–12 13 539 0.02 497.4
,12 17 741 0.02 523.3
Table 3. Relationship between fungal peritonitis and gastrostomy
Gastrostomy?
Fungal peritonitis? No Yes Total
No 154 (83%) 32 (17%) 186
Yes 34 (76%) 11 (24%) 45
Total 188 43 231
P 5 0.26 by chi-square test
Table 4. Fungi isolated from peritonitis episodes
Type Frequency (%)
C. albicans 10 (23.8%) Fig. 1. Relationship between time of catheter removal following fungal
C. parapsilopsis 11 (26.2%) peritonitis (FP) diagnosis and subsequent dialysis modality. Symbols
C. tropicalis 7 (16.7%) are: ( ) maintained on peritoneal dialysis (PD); ( ) converted to
C. rugosa 1 (2.4%) hemodialysis (HD).
C. guillermondii 1 (2.4%)
Candida sp. 3 (7.2%)
Cryptococcus laurent 1 (2.4%)
Flavimonas oryzihalsitaus 1 (2.4%)
Table 5. Patient outcome six months after fungal peritonitisTorulopsis glabrata 1 (2.4%)
Histoplasma capsulatum 1 (2.4%) Patients
Ustilago sp. 1 (2.4%) Outcome (N 5 51)
Other 4 (9.6%)
Return native function 2 (4%)
D/C dialysis 1 (2%)
HD 12 (24%)
PD 27 (53%)
Transplant 4 (8%)tomy tube/button at the time the infection was diag-
Death 3 (6%)
nosed. However, a comparison of data from these 45 Unknown 2 (4%)
patients and 186 age-matched controls, 17% of whom Abbreviations are: D/C, discontinued; HD, hemodialysis; PD, peritoneal dial-
ysis.had a gastrostomy, failed to yield a statistically significant
relationship between the infection and the presence of
a gastrostomy (P 5 0.26; Table 3).
Thirty-three (79%) of 42 FP episodes were caused by Six months after diagnosis, 27 (53%) of 51 patients
Candida species. Candida albicans, C. parapsilopsis, and remained on PD. Twelve (24%) patients were receiving
C. tropicalis accounted for the majority of these infec- HD, and three (6%) patients had died, in each case for
tions (Table 4). reasons unrelated to their FP episode (Table 5). All
Treatment included catheter removal in 46 (90%) of five patients whose treatment did not include catheter
the 51 FP episodes. Eight of 38 catheters were removed removal were living and being maintained on PD. There
within one day of diagnosis, whereas 18 catheters were was no significant relationship noted between the con-
not removed for four or more days after diagnosis (Fig. 1). version to HD and either the specific type of FP (P 5
A variety of antifungal medications were used. Ampho- 0.147), the use of combination (.2) antifungal drug ther-
tericin B, provided by the intravenous (30 episodes) or apy (P 5 0.179), or the time of catheter removal follow-
intraperitoneal (IP; 11 episodes) route, was used most ing the diagnosis of peritonitis.
frequently. Flucytosine and Fluconazole were used for Finally, the outcome of the 13 patients who initiated
treatment of 13 episodes and 11 episodes of FP, respec- dialysis within the first year of life and who developed FP
tively. More than one antifungal agent was used to treat is included in Table 6. Six months after diagnosis, 2 of the
13 patients had a return of their native kidney function.23 of 42 infections.
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Table 6. Outcome of patients with fungal peritonitis who initiated dialysis at age 0–1 year
6 months after 1 year after Age at initial
Patient FP diagnosis FP diagnosis Gastrostomy? FP diagnosis years
1 PD PD No 1.38
2 PD PD No 1.15
3 PD PD Missing Missing
4 Native function returned Transplanted Yes 0.83
5 PD Unknown Yes 0.11
6 PD Unknown No 0.11
7 PD PD No 2.35
8 PD PD Yes 1.05
9 PD PD Yes 2.68
10 PD PD No 2.22
11 Native function returned Native function Yes 1.08
12 Died — No 0.06
13 PD PD No 0.73
Abbreviations are: FP, fungal peritonitis; PD, peritoneal dialysis.
One patient had died, and 10 patients remained on PD. and possible transmural migration into the peritoneal
cavity. In the report of Goldie et al, nearly 65% of adultOne year after diagnosis, eight patients remained on PD.
patients who developed FP had received broad-spectrum
antibiotics within the preceding month, and 74% of pa-
DISCUSSION tients had received antibiotics within the preceding three
Fungal peritonitis is an infrequent complication of months [10]. Interestingly, Rubin et al did not report
chronic PD in children and adults [1, 2, 8, 9]. It represents any prior antibiotic exposure in a review of 17 cases of
less than 2% of peritonitis episodes in both patient popu- FP [11]. In a pediatric report, Mocan et al described six
lations. However, its importance resides in the dispro- children who developed FP, and all were being treated
portionately greater morbidity and mortality that has with IP antibiotics when the diagnosis of FP was made
historically been associated with this infection. [4]. Likewise, Oh et al [3], Enriquez, Kalia, and Travis
The infrequent nature of FP has resulted in the publi- [6], and Montane et al [7] described prior antibiotic usage
cation of a limited number of clinical experiences on the in two of two, six of nine, and six of six children diagnosed
topic. In the largest series, Goldie et al reported on the with FP, respectively [3, 6, 7]. In the current experience,
course of 55 episodes of FP in adults that represented a substantial percentage of patients who developed FP
3.2% of the peritonitis episodes diagnosed over a 10 year reportedly had not received a recent course of antibiot-
period in a single center [10]. Our ability to collect data ics. However, it is possible that many of the children
from multiple centers has allowed us to characterize the were prescribed antibiotics for treatment of nondialysis-
course of FP in 51 children, which represents the largest related infections common to the pediatric population
reported pediatric experience, to our knowledge. The and that the data were not available for this review.
fact that our peritonitis episodes represented 2.9% of The fact that only a minority of the FP episodes were
1729 peritonitis cases, values remarkably similar to those preceded by bacterial peritonitis was most surprising and
of Goldie et al, provide evidence that the risk of devel- emphasizes the need to consider FP in all patients who
oping FP in patients receiving chronic PD is similar for are unresponsive to the routine therapy used to treat
children and adults. While our data also suggest that the bacterial peritonitis.
risk of FP may be greatest for the youngest children, Based on an experience with three children who were
this finding is likely a reflection of the latter group’s severely malnourished when placed on PD, Murugasu
greater predisposition to all dialysis-related infections as et al suggested that the presence of a gastrostomy is a
previously reported by the NAPRTCS [1, 2]. In their significant risk factor for the development of FP and
1996 report, patients less than 2 years of age and more should be avoided in children on PD [5]. The three chil-
than 12 years had annualized peritonitis rates of 1.21 dren in that report developed Candida peritonitis one
and 0.82, respectively [1]. month, two months, and two years following the inser-
Several factors appear to predispose patients to the tion of a gastrostomy, respectively. Until now, the lack
development of FP. The most consistently reported fac- of a large pediatric patient population with FP has pre-
tor is the use of antibiotics to treat bacterial peritonitis cluded further evaluation of this proposed association.
or a catheter-related infection prior to the development Our ability to study this issue in 45 patients with a history
of the fungal infection. Presumably, antibiotic therapy of FP and four times as many control patients now pro-
vides evidence that there is no statistically significantmodifies the fecal flora, prompting overgrowth of fungi
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association between the presence of a gastrostomy and undetermined. Most clinicians favor catheter removal
and consider it the cornerstone of therapy [8], as oc-the development of FP. Nevertheless, care providers
should evaluate the gastrostomy tube/button exit site curred with all but five of the patients in this report. The
suggested need for catheter removal is based on thedaily because of the recognized risk for infection and
the potential for cross-contamination of the PD catheter premise that the fungus usually colonizes the catheter.
In turn, the colonization prevents eradication of the in-exit site. It has also been suggested that infectious com-
plications of a gastrostomy may be minimized by de- fection despite drug therapy. What remains a matter of
dispute is the timing of catheter removal; should it occurlaying placement of the gastrostomy in severely malnour-
ished patients on PD until the nutritional status is at the time of FP diagnosis or should it be delayed,
allowing for a period of peritoneal lavage with hopes ofimproved using alternative routes of enteral support (for
example, nasogastric tube) [12]. preventing formation of peritoneal adhesions and main-
taining viability of the peritoneal membrane for dialysis?Johnson et al have suggested that the dialysis modality
may influence the risk of peritonitis [13]. In their report, The majority of the patients described by Goldie et al
had their catheters removed between the third and sev-the incidence of FP was lower among patients on APD
compared with those on continuous ambulatory PD enth days after presentation [10]. In those patients whose
catheters were later replaced, 91 and 60%, respectively,(CAPD), presumably because of the fewer number of
monthly connections and disconnections. Two thirds of were able to continue PD one and six months after cathe-
ter replacement. Although our data on this issue derivedour patients with and without a history of FP received
APD. Likewise, although an upward-directed PD access from 38 cases of FP also appear to question the need
for immediate catheter removal, prospective evaluationexit site is a recognized risk factor for peritonitis in chil-
dren [1, 2], there were no differences in the access charac- of this important component of therapy is clearly neces-
sary.teristics of the two patient groups in the current analysis.
The previously mentioned association between antibi- Medical therapy of FP has most often consisted of
intravenous Amphotericin B, as reflected by our dataotic therapy and the development of FP has prompted
the institution of several trials of antifungal prophylaxis and that of others [5, 6, 9]. While some of the patients
in this report also received IP Amphotericin B, the IPduring a course of antibiotic therapy. Zaruba, Peters,
and Jungbluth, using oral Nystatin, reported a reduced route is characteristically irritating to the peritoneum
and may result in severe abdominal pain [18]. Morerisk of antibiotic-related FP from 10.5% of all peritonitis
episodes to 3.1% of episodes [14]. Lo et al also concluded recently, it has become evident that Amphotericin B
actually has poor peritoneal penetration in contrast tothat oral Nystatin prophylaxis reduces the risk of second-
ary Candida peritonitis [15], while Thodis et al did not Fluconazole, a triazole with excellent bioavailability [19].
Although used in a minority of cases presented in thisconfirm this finding [16]. In a pediatric experience, Robi-
taille et al reported a significant decrease in the incidence report, Fluconazole is currently the drug of choice for
most Candida species other than C. krusei and someof FP episodes in patients who received either oral Ny-
statin or Ketoconazole throughout each course of antibi- isolates of C. glabrata [7, 8]. In fact, it has been suggested
that in some instances, the combination of Fluconazoleotic therapy [17]. Our data were insufficient to draw any
meaningful conclusion about the benefits of antifungal and Flucytosine may provide effective treatment for FP
without the need for simultaneous catheter removalprophylaxis. Our finding that one half of the patients who
received some form of antifungal prophylaxis developed [8, 20].
The outcome of FP is typically poor, with CAPD drop-peritonitis emphasizes the need to study this issue further
in a prospective manner. out common and patient mortality rates in adults ranging
from 17 to 44% [10, 11, 16, 21, 22]. In contrast, nearlyTypically, Candida species account for the majority of
fungal isolates, with C. albicans being the most common. 70% of the patients in the NAPRTCS registry (including
infants) who were receiving dialysis six months after theIn the patients of Goldie et al, C. albicans and C. parapsi-
lopsis each accounted for 25% of infections and Candida diagnosis of FP were able to be maintained on PD. In
addition, no patient died as a direct result of their fungalspecies accounted for 75% of all infections [10]. Simi-
larly, Enriquez et al detected a Candida species in all infection. While the reasons behind the apparently more
favorable outcome in children versus adults are un-nine children reported from their single center [6]. Our
results were remarkably similar to those of Goldie et al, known, it may be related in part to the less frequent
presence of significant comorbidities (for example, im-as C. albicans and C. parapsilopsis each accounted for
approximately 25% of the isolates and Candida species munocompromised, serious underlying illness) in the
children being dialyzed and the greater acceptance ofrepresented nearly 79% of all infections. Infections with
filamentous fungi were rare in both our series and that long-term HD in adults.
In summary, FP is an infrequent cause of peritonitisof Goldie et al.
The optimal approach to the treatment of FP remains in children receiving chronic PD. The presence of a gas-
Warady et al: Fungal peritonitis in children 389
10. Goldie SJ, Kiernan-Troidle L, Torres C, Gorban-Brennan N,trostomy does not appear to predispose patients to the
Dunne D, Kliger AS, Finkelstein FO: Fungal peritonitis in a large
development of this infection, and successful therapy chronic peritoneal dialysis population: A report of 55 episodes. Am
J Kidney Dis 28:86–91, 1996most often consists of a combination of antifungal medi-
11. Rubin J, Kirchner K, Walsh D, Green M, Bower J: Fungalcation and dialysis catheter removal. Future investigative
peritonitis during continuous ambulatory peritoneal dialysis: A
efforts in this area should address preventive measures report of 17 cases. Am J Kidney Dis 10:361–368, 1987
12. Watson A, Coleman J, Warady BA: When and how to use naso-and include an evaluation of the efficacy of prophylactic
gastric and gastrostomy feeding for nutritional support in infantsantifungal regimens with agents such as Fluconazole.
and children on CAPD/CCPD, in Chronic Ambulatory Peritoneal
Dialysis (CAPD) and Chronic Cycling Peritoneal Dialysis (CCPD)Reprint requests to Dr. Bradley A. Warady, The Children’s Mercy
in Children (2nd ed), edited by Fine RN, Alexander SR, WaradyHospital, 2401 Gillham Road, Kansas City, Missouri 64108, USA.
BA, Boston, Kluwer Academic Publishers Group, 1998, pp 281–300E-mail: bwarady@cmh.edu
13. Johnson RJ, Ramsey PG, Gallagher N, Ahmad S: Fungal perito-
nitis in patients on peritoneal dialysis: Incidence, clinical features
and prognosis. Am J Nephrol 5:169–175, 1985REFERENCES
14. Zaruba K, Peters J, Jungbluth H: Successful prophylaxis for
1. Lerner GR, Warady BA, Sullivan EK, Alexander SR: Chronic fungal peritonitis in patients on continuous ambulatory peritoneal
dialysis in children and adolescents. Pediatr Nephrol 13:404–417, dialysis: Six years’ experience. Am J Kidney Dis 17:43–46, 1991
1999 15. Lo W-K, Chan C-Y, Cheng S-W, Poon JF-M, Chan DT-M, Cheng
2. Warady BA, Sullivan EK, Alexander SR: Lessons from the IK-P: A prospective randomized control study of oral nystatin
peritoneal dialysis patient database: A report of the North Ameri- prophylaxis for candida peritonitis complicating continuous ambu-
can Pediatric Renal Transplant Cooperative Study. Kidney Int latory peritoneal dialysis. Am J Kidney Dis 28:549–552, 1996
49:S68–S71, 1996 16. Thodis E, Vas SI, Bargman JM, Singhal M, Chu M, Oreopoulos
3. Oh S-H, Conley SB, Rose GM, Rosenblum M, Kohl S, Pickering G: Nystatin prophylaxis: Its inability to prevent fungal peritonitis
LK: Fungal peritonitis in children undergoing peritoneal dialysis. in patients on continuous ambulatory peritoneal dialysis. Perit Dial
Pediatr Infect Dis 4:62–66, 1985 Int 18:583–589, 1998
4. Mocan H, Murphy AV, Beattie TJ, McAllister TA: Fungal 17. Robitaille P, Merouani A, Clermont M-J, Hebert E: Successful
peritonitis in children on continuous ambulatory peritoneal dial- antifungal prophylaxis in chronic peritoneal dialysis: A pediatric
ysis. Scot Med J 34:494–496, 1989 experience. Perit Dial Int 15:77–79, 1995
5. Murugasu B, Conley SB, Lemire JM, Portman RJ: Fungal perito- 18. Arfania D, Everett D, Nolph KD, Rubin J: Uncommon causes
nitis in children treated with peritoneal dialysis and gastrostomy of peritonitis in patients undergoing peritoneal dialysis. Arch Intern
feeding. Pediatr Nephrol 5:620–621, 1991 Med 141:61–64, 1981
6. Enriquez JL, Kalia A, Travis LB: Fungal peritonitis in children 19. Blowey DL, Garg UC, Kearns GL, Warady BA: Peritoneal
on peritoneal dialysis. J Pediatr 117:830–832, 1990 penetration of amphotericin B lipid complex and fluconazole in a
7. Montane BS, Mazza I, Abitbol C, Zilleruelo G, Strauss J, pediatric patient with fungal peritonitis, in Advances in Peritoneal
Coakley S, Diaz R: Fungal peritonitis in pediatric patients, in Dialysis (vol 14), edited by Khanna R, Toronto, Multimed Inc.,
Advances in Peritoneal Dialysis (vol 14), edited by Khanna R, 1998, pp 247–250
Toronto, Multimed Inc., 1998, pp 251–254 20. Nagappan R, Collins JF, Lee WT: Fungal peritonitis in continuous
8. Keane WF, Alexander SR, Bailie GR, Boeschoten E, Gokal ambulatory peritoneal dialysis: The Auckland experience. Am J
R, Golper TA, Holmes CJ, Huang C-C, Kawaguchi Y, Piraino Kidney Dis 20:492–496, 1992
B, Riella M, Schaefer F, Vas S: Peritoneal dialysis-related perito- 21. Michel C, Courdavault L, Al Khayat R, Viron B, Roux P,
nitis treatment recommendations: 1996 update. Perit Dial Int Mignon F: Fungal peritonitis in patients on peritoneal dialysis.
16:557–573, 1996 Am J Nephrol 14:113–120, 1994
9. Saran R, Goel S, Khanna R: Fungal peritonitis in continuous 22. Cheng IK, Fang GX, Chan TM, Chan PC, Chan MK: Fungal
ambulatory peritoneal dialysis. (editorial) Int J Artif Organs 19: peritonitis complicating peritoneal dialysis: Report of 27 cases and
441–445, 1996 review of treatment. Q J Med 71:407–416, 1989
